PamGene and JPT join forces

Dutch company PamGene International and Jerini Peptide Technologies (JPT), a division of Berlin-based Jerini, have established a collaboration to provide a new technology for kinase studies.

PamGene's ability to generate kinetic read-out of multiple kinase activities on its 3-D microarray platform is complemented by JPT's advanced peptide expertise and extensive peptide libraries. The joint product offering has been designed to provide significant benefits to signal transduction-focused medicinal chemistry groups.

Both companies are already active in the kinase field and the technology combination is expected to provide specific advantages for lead generation and optimisation by providing comprehensive characterisation of lead compounds, including selectivity, potency (IC50) and mechanism of action information.

'One of the main challenges in pharma r&d is improving compound selection. With PamGene's 96-well array platform and JPT's kinase peptide substrates, it is now possible to generate kinetic read-out of multiple kinase activities in one experiment,' explained Dr Rob Ruijtenbeek, head of kinase research at PamGene.

'Additionally, we can analyse multiple conditions on a single plate, e.g. inhibitor concentration series. The high content and high quality kinetic data will allow much more intelligent selection and prioritisation of leads that enter the subsequent expensive stages of drug development.'